In an effort to bring the use of Oxycodone CR under more effective control, H.R. 1366 cited as the “Stop Oxy Abuse Act of 2013” was introduced “to direct the Commissioner of Food and Drugs to modify the approval of any drug containing controlled-release (CR) oxycodone hydrochloride, to limit such approval to use for the relief of severe-only instead of moderate-to-severe pain, and for other purposes”.
No Comments
Filed under:
Clinical Practices, Gould & Lamb News, Life Care Plan, Medicare Secondary Payer Compliance, Pharmaceutical
Tags: beneficiary, controlled substance, Drug Control, drugs, FDA, future care, HR 1366, medication, off-label, Oxycodone, pain management, Part D, pharmacy, prescription, recovery, Rx, Workers’ Compensation
Tags: beneficiary, controlled substance, Drug Control, drugs, FDA, future care, HR 1366, medication, off-label, Oxycodone, pain management, Part D, pharmacy, prescription, recovery, Rx, Workers’ Compensation
On Thursday, April 25, 2013 Panelists John P Albert - Acting Director, Division of Medicare Secondary Payer Policy and Operations; Cynthia Gross - Health Insurance Specialist, Division of Medicare Secondary Payer Policy and Operations; Elizabeth V. Poole - Health Insurance Specialist, Division of Medicare Secondary Payer Policy and Operations; and Barbara Jean Wright - Senior Technical Advisor, MSP were welcomed by almost 200 members of the National Alliance of Medicare Set Aside Professionals at its annual conference in Baltimore, Maryland.
The United States House of Representatives today passed the Saving Medicare and Repaying Taxpayers (SMART) Act as part of a broader legislative effort. The SMART Bill was attached to... 
